Antiviral activity of Anaferon (pediatric formulation) in mice infected with pandemic influenza virus A(H1N1/09).

Abstract

Anaferon (pediatric formulation) administered in the therapeutic-and-prophylactic regimen to mice receiving intranasally 100% infecting dose of A/California/07/2009(H1N1)v influenza virus exhibited an antiviral effect and 10-fold reduced the production of influenza virus in the lungs of infected mice on days 4, 6, and 8 after infection compared to the control (distilled water). The efficiency of Anaferon (pediatric formulation) administered before and after infection with A/California/07/2009(H1N1)v influenza virus was not inferior to the use of Tamiflu after infection.

• Authors: L N Shishkina, M O Skarnovich, A S Kabanov, A A Sergeev, S E Olkin, S A Tarasov, M V Belopolskaya, S A Sergeeva, O I Epstein, E M Malkova, E A Stavsky, I G Drozdov
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 149 Issue 5 Pg. 612-4 (Oct 2010) ISSN: 1573-8221 [Electronic] United States
• PMID: 21165400 (Publication Type: Journal Article)

Chemical References

• Antibodies
• Antiviral Agents
• anaferon
• Oseltamivir

Topics

• Animals
• Antibodies (therapeutic use)
• Antiviral Agents (therapeutic use)
• Influenza A Virus, H1N1 Subtype (drug effects)
• Lung (virology)
• Mice
• Mice, Inbred BALB C
• Orthomyxoviridae Infections (drug therapy, virology)
• Oseltamivir (therapeutic use)